Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.

Biology of the neonate2005Schmidt B

Study designReview

SubjectHuman

Record checks

Study design: Review
Subject: Human
Publication year: 2005
Source: doi.org
Abstract display: Not reproduced here
Publication status: Active
Status checked: 17 Aug 2026
Collected: 3 Aug 2026
Freshness: Current
Review stage: Automated
Record status: Published

How to read this record →

Abstract

cc by 以外（cc by-nc / cc by-nc-nd / NONE 等）は抄録を再掲しない。DOI/PMID へのリンクのみ表示する。

MeSH

AgingApneaBlindnessCerebral PalsyCognition DisordersDeafnessFollow-Up StudiesHumansInfant MortalityInfant, NewbornInfant, Premature, DiseasesPlacebosRandomized Controlled Trials as TopicRisk AssessmentTreatment OutcomeXanthines

DOI 10.1159/000087584

PMID 16210843

View source →